Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
John Corea

John Corea John Corea is Deputy Vice President, Policy & Research at the Pharmaceutical Research and Manufacturers of America. At PhRMA, John commissions and oversees research projects that further policymakers’ and the public’s understanding of the U.S. biopharmaceutical industry and its role in the healthcare system. He manages a range of issues related to the economics of R&D, the economic impact of the biopharmaceutical industry, and putting the cost of medicines into context. In his more than two decades of experience in health policy and healthcare economics research and consulting, John has advised or consulted for stakeholders in nearly every corner of American health care. Before joining PhRMA, John spent the largest part of his career at The Lewin Group, a nationally-renowned health policy consulting firm based in Falls Church, Virginia. He has a BA in Economics from the University of Pennsylvania.

Recent Posts

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

By John Corea  |    July 7, 2022
As the world braves year three of the COVID-19 pandemic and confronts a virus that continues to evolve and challenge us, we’ve come a long way in how we combat this ongoing threat. Since the start of...   Read More

New report demonstrates development of new medicines relies on private sector expertise and investment

By John Corea  |    May 10, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. Critical to this...   Read More

Clinical trials impact state economies

By John Corea  |    May 3, 2019
A new report from TEConomy Partners, supported by PhRMA, provides estimates of industry-sponsored clinical trial activity in each of the 50 states, including the number of trials active, the number...   Read More

Examining the truth behind clinical trial costs

By John Corea  |    October 2, 2018
Last week, a study appearing in the Journal of the American Medical Association (JAMA) Internal Medicine, evaluated the costs specifically associated with successful clinical trials for novel...   Read More

New PhRMA resources chock full of biopharma industry facts

By John Corea  |    July 20, 2017
Did you know that PhRMA member companies invested $65.5 billion in research and development (R&D) in 2016? Or that combined spending on brand medicines, generics and the supply chain account for 14...   Read More

New Report: Clinical Trials and the Impact on State Economies

By John Corea  |    March 12, 2015
Beyond the profound value that biopharmaceutical industry research and development (R&D) brings patients – new treatments and potential cures for society’s most devastating and costly diseases – are...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates